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ABSTRACT Full-length human immunodeficiency virus type 1 (HIV-1) RNA serves as
the genome or as an mRNA, or this RNA undergoes splicing using four donors and
10 acceptors to create over 50 physiologically relevant transcripts in two size classes
(1.8 kb and 4 kb). We developed an assay using Primer ID-tagged deep sequencing
to quantify HIV-1 splicing. Using the lab strain NL4-3, we found that A5 (env/nef) is
the most commonly used acceptor (about 50%) and A3 (tat) the least used (about
3%). Two small exons are made when a splice to acceptor A1 or A2 is followed by
activation of donor D2 or D3, and the high-level use of D2 and D3 dramatically re-
duces the amount of vif and vpr transcripts. We observed distinct patterns of tem-
perature sensitivity of splicing to acceptors A1 and A2. In addition, disruption of a
conserved structure proximal to A1 caused a 10-fold reduction in all transcripts that
utilized A1. Analysis of a panel of subtype B transmitted/founder viruses showed
that splicing patterns are conserved, but with surprising variability of usage. A sub-
type C isolate was similar, while a simian immunodeficiency virus (SIV) isolate
showed significant differences. We also observed transsplicing from a downstream
donor on one transcript to an upstream acceptor on a different transcript, which we
detected in 0.3% of 1.8-kb RNA reads. There were several examples of splicing sup-
pression when the env intron was retained in the 4-kb size class. These results dem-
onstrate the utility of this assay and identify new examples of HIV-1 splicing regula-
tion.
IMPORTANCE During HIV-1 replication, over 50 conserved spliced RNA variants are
generated. The splicing assay described here uses new developments in deep-
sequencing technology combined with Primer ID-tagged cDNA primers to efficiently
quantify HIV-1 splicing at a depth that allows even low-frequency splice variants to
be monitored. We have used this assay to examine several features of HIV-1 splicing
and to identify new examples of different mechanisms of regulation of these splic-
ing patterns. This splicing assay can be used to explore in detail how HIV-1 splicing
is regulated and, with moderate throughput, could be used to screen for structural
elements, small molecules, and host factors that alter these relatively conserved
splicing patterns.
KEYWORDS HIV-1, RNA splicing, next-generation sequencing, primer ID, simian
immunodeficiency virus
Human immunodeficiency virus type 1 (HIV-1) is a plus-stranded RNA virus thatreplicates through an obligatory integrated DNA intermediate. The virus carries 10
genes and uses several different strategies to allow expression of these genes, given
that eukaryotes typically translate only the first open reading frame (ORF) of an mRNA.
Unspliced full-length transcripts code for the Gag and Gag-Pro-Pol polyproteins. The
remaining seven viral proteins are translated from over 50 mRNA variants generated by
the host cell splicing machinery (1).
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HIV-1 splicing has been extensively studied and the splice variants and splice
regulatory sequences have been well characterized (2, 3), most often using the labo-
ratory strain NL4-3. Approximately one-half of the initial full-length transcripts remain
unspliced and serve either as genomic RNA or as mRNA for the Gag and Gag-Pro-Pol
polyproteins (Fig. 1). The remaining half of the full-length transcripts are spliced (1). All
spliced RNAs use donor site 1 (D1) in the 5= noncoding region and 1 of 10 downstream
acceptor sites (A1, A2, A3, A4a, A4b, A4c, A4d, A5, A5b, A7) (2, 4). About half of the
spliced RNAs also undergo further splicing to remove the D4-A7 env intron (2). These
smaller RNAs are referred to as the completely spliced or 1.8-kb size class. Spliced RNAs
that retain the D4-A7 intron are known as the incompletely spliced or 4-kb size class.
Completely spliced transcripts are exported from the nucleus via cellular mRNA path-
ways; however, the incompletely spliced and full-length transcripts require a viral
protein, Rev, for nuclear export. The D4-A7 intron contains the Rev binding sequence
RRE (Rev response element). With increasing concentrations of Rev, the expression
pattern is altered by allowing incompletely spliced RNAs to exit the nucleus (5, 6). As
a rule, the major splice products are produced from a direct splicing event between D1
and one of the acceptor sites (Fig. 1). The ensuing transcript is generally translated from
the first ORF downstream of this direct splice junction. Thus, D1-A1 splicing makes a vif
transcript, D1-A2 a vpr transcript, and so on. The facts that D1 is engaged as a splice
donor in only a fraction of the full-length transcripts, that D1 splicing must singly
engage a number of different downstream splice acceptor sites, and that splicing of the
D4-A7 intron is itself regulated all point to a highly orchestrated pattern of splicing to
allow adequate expression of each of the viral proteins.
Even greater splicing complexity comes from the use of two additional donor sites,
D2 and D3, that create two small exons, A1-D2 and A2-D3, one or both of which may
be included in splice variants for the downstream genes (2). The purpose of these small
exons is unknown, and they are present in only a small fraction of RNAs. They do not
code for any known regulatory elements or alternative proteins, and mutations that
prevent their use have shown contradictory results regarding fitness, transcript stability,
and splicing effects (1, 7–10). Other studies have searched for regulatory sequence
elements around the major splice acceptors, and different types of regulatory elements
that control the utilization of splice sites have been identified (10–13). Sequence
elements outside the specific splice site sequences bind cellular factors that enhance or
suppress donor or acceptor usage, often in a concerted or competitive manner (14, 15).
Mutations in these elements have been reported to alter splicing (1, 2).
The major splicing elements of HIV-1 subtypes B and C were originally defined using
assays that require reverse transcription (RT)-PCR amplification of splice variants fol-
lowed by cloning and sequencing of clones. Another approach to assaying splicing has
been to identify the RT-PCR products of the individual splice variants by size (2, 16).
FIG 1 HIV-1 splice patterns and primer locations. Blue, forward primer; red, 1.8-kb class Primer ID-tagged reverse primer; green, 4-kb class Primer ID-tagged
reverse primer. Gray boxes are small exons or sequences that may or may not be present in the respective transcripts. Adapted from Purcell and Martin (2).
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Studies assessing the effects of control element mutations on splicing have often been
done using incomplete viral RNAs, such as single-intron minigenes, simplifying the
analysis but placing splicing outside the context of the entire viral genome. More
recently, a deep-sequencing approach used the PacBio platform with its long read
capability to characterize HIV-1 splicing in extensive detail. This approach confirmed
the previously described splice variants and discovered new ones (3).
Here we report a new assay to analyze HIV-1 splicing based on the Illumina MiSeq
deep-sequencing platform. We used the assay to quantify the splicing patterns within
each mRNA size class in HIV-1NL4-3 infection and after transfection of an infectious
clone. We quantified acceptor usage and the differential usage of minor splice donors
D2 and D3 in the two mRNA size classes, one of several examples in which splicing was
differentially regulated between the two size classes. We observed that two silent
mutations designed to disrupt a conserved element of secondary structure, SLSA1
(stem-loop containing splice acceptor A1), caused a 10-fold decrease in splicing to A1,
linking this feature of secondary structure to regulation of A1 usage. We examined the
stability of splicing as a function of temperature and observed two distinct patterns of
temperature sensitivity, with splicing to A2 increased at the lower temperature but
inhibited at the higher temperature while splicing to A1 was just inhibited at the higher
temperature. We found that the combined effects of the SLSA1 mutation and temper-
ature were additive in their effects on A1. We also examined the extent to which
complex splicing patterns are conserved by assaying splicing in a panel of transmitted/
founder (T/F) viruses, which showed that most features of HIV-1 splicing are highly
conserved, although examples of variability in the frequency of use were seen. We
adapted the assay to quantify splicing in a subtype C isolate and found high conser-
vation compared to subtype B. Analysis of splicing in a simian immunodeficiency virus
(SIV) isolate revealed many conserved features but also significant differences. We
detected transsplicing between different transcripts and even between transcripts from
different proviruses. Collectively, these results provide greatly enhanced quantification
of splicing in the context of viral infection and offer new insights into HIV-1 splicing and
its regulation.
RESULTS
Description of a new splicing assay.We developed a new HIV-1 splicing assay that
combines deep sequencing with the previously developed Primer ID technology (17).
In this assay, total cellular RNA from infected or transfected cells is extracted and used
in two different cDNA reactions, each one specific to the two viral mRNA size classes
(1.8 kb and 4 kb). The 3= end of the cDNA primer used to capture the 4-kb size class of
viral RNAs is placed near the 5= end of the D4-A7 env intron (Fig. 1, shown in green).
This intron is removed from the 1.8-kb size class RNAs, so this primer is specific for the
4-kb class. The cDNA primer for the 1.8-kb class is shown in red. The 3= end of this
primer spans the D4-A7 splice junction, which forms only in the 1.8-kb RNAs. Each of
the cDNA primers includes a common sequence at its 5= end that serves as the
sequence of the reverse primer in PCR. The forward PCR primer, shown in blue in Fig.
1, is upstream of D1 and is used in the PCR amplification of both size classes.
The Primer ID portion of the cDNA primer is an internal random sequence tag in the
primer that is used to identify and quantify individual viral RNA templates. The cDNA
primers are synthesized with this internal random nucleotide sequence block. This
creates random combinations of primer tags. Given a sufficient excess of random
sequence tags relative to sample templates, any one viral RNA template will be primed
with a unique random sequence in the cDNA primer that is then incorporated into the
cDNA. The same sequence tag, present in the cDNA primer, will be present on all PCR
products that come from this one viral RNA template. The cDNAs are then PCR
amplified, made into an Illumina library, and sequenced using Miseq paired-end
sequencing. Each sample produces millions of sequence reads. In the Illumina paired-
end method, each read contains approximately 300 bases starting from the forward
primer and, similarly, a corresponding 300-base reverse sequence beginning with the
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Primer ID and reverse primer that is paired to the read from the other end. The
combined information from the paired-end reads is sufficient to distinguish all splice
variants except nef 1 (a direct splice from D1 to A7), which lies outside the primer range.
The inclusion of Illumina-indexed linkers allows multiplexing of multiple samples in a
single sequencing run.
A sorting program first reads the forward sequence and identifies the donor and
acceptor sites in the spliced RNA template and then does the same for the reverse read
and combines the information to give a pattern of splice junctions. These patterns are
sorted according to Primer ID. All reads with the same Primer ID sequence are
condensed into a single splice junction pattern, and that pattern is matched to a known
splice variant. Regardless of the number of times a specific Primer ID sequence occurs
in the sequencing output, each unique Primer ID tag is counted as a single observation
of an mRNA molecule. For the reported experiments, the sequencing depth typically
ranged from 100,000 to 500,000 unique Primer IDs, indicating that this number of
independent mRNA templates were queried, allowing the accurate quantification of
the normal viral spliced RNAs and the reliable detection of rare or cryptic events.
Quantification of acceptor splice site usage in NL4-3. CEMx174 cells were in-
fected with HIV-1NL4-3, and the cells were grown in culture until syncytia formed, as
evidence of a robust but asynchronous infection. Total cellular RNA was extracted and
used as input for the sequencing and quantification of spliced viral mRNAs. An
overview of the data is as follows. Essentially, all spliced viral transcripts use D1 and
splice to a downstream acceptor site. Although there are multiple A4 and A5 acceptors,
they are grouped together (as A4 or A5) in the figures. The relative usage of each
acceptor for both size classes is shown in Fig. 2A. The patterns are somewhat similar in
the two size classes, with env A5 as the most commonly used acceptor and tat A3 the
least used acceptor. A previous study suggested that HIV-1 splicing is sequential (18),
and the relative proportions in each size class suggests that the choice of upstream
splice acceptor site differentially influences downstream splicing (i.e., of the D4-A7
intron). A transcript spliced from D1 to A1, A3, or A4 has an increased probability of
splicing from D4 to A7 and so of being a 1.8-kb transcript. In contrast, a splice between
D1 and A2 does not affect the use of D4 and A7, while splicing from D1 to A5 skews
toward suppressing the use of D4 and A7, thereby including the env intron (a 4-kb
transcript). Thus, the use of D4 and A7 appears to be differentially impacted by the
choice of the upstream splice acceptor by D1.
Splicing events from D1 to A1 or A2 initially make a vif or vpr mRNA, respectively.
However, a splice to A1 most often splices again by utilizing the nearby downstream
donor D2 to create small exon 1 (SX1), with D2 splicing to one of the other downstream
acceptor sites, A2 to A5 (Fig. 2B). Thus, the initial splicing to A1 results in a relatively low
number of vif transcripts in both size classes, with the use of D2 reducing the potential
number of vif transcripts by over 95%.
The splicing events from D1 to A2 have a different outcome in the two size classes
with respect to the utilization of the adjacent D3 donor to generate SX2 (Fig. 2C). In the
1.8-kb class, most A2 splices utilize D3 to create small exon 2 and then splice again to
A3, A4, or A5; however, in the 4-kb class, 31% of splices to A2 remain as vpr transcripts.
This suggests that D3 usage affects downstream D4 usage, such that the inclusion of
SX2 (i.e., the use of D3) increases the probability of splicing from D4 to A7 with removal
of the env intron. Alternatively, the same mechanism that suppresses D4 utilization to
create the 4-kb env mRNA may also suppress utilization of D3.
Transcripts with either or both of the small exons are present at twice the frequency
in 1.8-kb transcripts compared to 4-kb transcripts (Fig. 2D), an observation that is
partially driven by the disproportionate inclusion of small exon 2 in the 1.8-kb mRNAs
(Fig. 2C) but primarily driven by the increased use of A1 (and the small exon from
A1-D2) in the 1.8-kb mRNAs (Fig. 2A and B). This suggests that inclusion of small exons
upregulates splicing from D4-A7. It is curious that in the vast majority of cases, splicing
to A1/vif and A2/vpr are followed by subsequent splicing at D2 and D3, respectively;
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however, the majority of the A3-A5 transcripts are the result of a direct splice from D1
and do not include the small exons (Fig. 2D). This suggests that the main functions of
D2 and D3 are to downregulate the expression of vif and vpr beyond what can be
accomplished through differential splicing among the splice acceptor sites. The high-
frequency use of D2 and D3 would also be expected in exon definition (discussed
below); however, this highlights the unexpected difference in D3 use between the size
classes. In this analysis, we have likely underestimated A1 and A2 usage due to
differences in the length of cDNA product needed to see splicing to the proximal splice
acceptor sites A3-A5 (within 300 nucleotides) compared to the distance from the cDNA
primer to A1 (1,100 nucleotides); however, the use of Primer ID corrects for any
subsequent skewing in amplification efficiency of longer versus shorter PCR products.
Differential effects of temperature on splicing. HIV-1 splicing must function
through the presence of suboptimal splice donor and acceptor sites to allow a vast
array of splicing outcomes. Inefficient pairing of these suboptimal sites with the cellular
splicing machinery has been shown to affect donor and acceptor usage (10, 15, 19–21).
We reasoned that some of these interactions with the cellular splicing machinery could
be temperature sensitive. Temperature changes might also affect the stability of RNA
secondary structures that work in cis to regulate splicing. To test the effects of
temperature, a culture of CEMx174 cells infected with HIV-1NL4-3 was split into 3 flasks
that were then incubated for 6 h at 33°, 37°, or 41°C. At the end of 6 h, RNA was
extracted from the cells and the viral splice products were measured (Fig. 3). In general,
increasing temperature modestly upregulated splice variants without small exons 1 or
FIG 2 Quantification of HIV-1 splicing patterns. (A) Acceptor usage from D1 in the two size classes. Circles
represent all transcripts in the size class. (B) Circles represent the total splices from D1 to A1. Shown are
proportions that splice again at D2 and those that remain vif transcripts. (C) Circles represent the total
splices to A2 and the proportions that splice again at D3 compared to those that remain vpr transcripts.
(D) Circles represent all transcripts in the size class. Shown are proportions of transcripts that contain
either one, both, or no small exons. SX1, small exon 1; SX2, small exon 2.
HIV-1 Splicing with Next-Generation Sequencing Journal of Virology
March 2017 Volume 91 Issue 6 e02515-16 jvi.asm.org 5
2. However, splice acceptors A1 and A2 were very sensitive to temperature and showed
different responses to temperature changes. Splicing to A1 decreased with increasing
temperature, and this was seen for both the vif transcript and all transcripts that include
SX1 defined by A1 and D2 usage. Similarly, all splices to A2 also decreased with
increasing temperature but were additionally significantly upregulated at lower tem-
perature, including vpr transcripts and transcripts including SX2 between A2 and D3.
Transcripts that use both A1 and A2 showed the more dominant effect of A2 alone.
Thus, we see distinctive temperature sensitivities of the splice acceptor sites, with the
most sensitive being the sites associated with the generation of the small exons.
Changes in secondary structure can affect splicing. HIV-1 RNA has regions of
highly conserved secondary structure, and many of these structures have functional
relevance (19, 20, 22–27). These include the TAR binding site in the 5= untranslated
region (UTR), which binds the viral Tat protein and is required for processive transcrip-
tional elongation (28). The major splice donor D1 is also in this region as well as a
structure that regulates genome packaging (24) and the dimerization sequence. The
Rev response (binding) element (RRE), located in the env intron, also has features of
highly conserved secondary structure (29). Some splicing elements are contained in, or
are in close proximity to, conserved structural elements, and some of these structures
are well characterized (19, 21, 22, 26). This raises important questions about the role of
RNA structural elements in controlling splicing during viral infection and the impor-
tance of such structures for correct splicing.
A previous comparison of RNA secondary structure between HIV-1NL4-3 and
SIVmac239 revealed regions of highly conserved structure (22), one of which was a
stem-loop structure termed SLSA1 that contains the vif splice acceptor site A1 in the
loop. We previously engineered two silent point mutations to disrupt the SLSA1 stem
without changing the A1 splice acceptor sequence or nearby reported splice regulatory
sequences and noted a change in downstream splicing using an older, PCR product
size-based assay (22). We have reevaluated this mutant with the new deep-sequencing
assay and confirm an effect on splicing but can now identify it as an effect on the
proximal vif A1 splice acceptor site. RNA from CEMx174 cells infected with the SLSA1
mutant virus was processed in parallel with the RNA from cells infected with the
wild-type (WT)/parental strain NL4-3. These two point mutations resulted in an approx-
FIG 3 Temperature-dependent splicing regulation. Cells were infected with HIV-1 strain NL4-3, and after several days the culture was divided and
placed at the indicated temperatures for the last 6 h. Whole-cell RNA was extracted and viral RNA assessed for splicing. The histogram shows the
ratio of the percentage of each 1.8-kb transcript type relative to the 37°C sample (always at a 1:1 ratio with itself). Splice variants are grouped
by direct splice to the final acceptor or small exon inclusion. Stars indicate splices to A1 that make vif transcripts or splices to A2 that make vpr.
The x axis labels show the splice donors and acceptors used and the protein product of the transcript.
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imately 10-fold decrease in the utilization of A1 relative to the control, which was
reflected in the decrease of the direct splice to create vif mRNA and in RNAs containing
the first small exon from A1 to D2 (Fig. 4). Thus, the conserved SLSA1 stem-loop
structure containing the A1 splice site plays an important role in regulating the
utilization of that site.
Combined effects of temperature and structure. We next reasoned that the
temperature sensitivity of A1 might be related to the melting of the proximal conserved
stem-loop structure (SLSA1). This would predict that the SLSA1 mutant would not be
temperature sensitive for splicing to A1. To test this, we compared splicing across the
temperature range in the SLSA1 mutant with that in WT NL4-3, using the same strategy
as in the temperature gradient experiment. We saw that the effects of temperature and
the SLSA1 mutations were additive compared to the wild-type virus at 37°C, reducing
splicing to A1 to very low levels (Fig. 5A). When we focused on the effects of the
different temperatures within the context of reduced splicing of the SLSA1 mutant, we
saw that the patterns of increases and decreases of splice site usage as a function of
temperature were the same as those seen with wild-type virus (Fig. 5B). This suggests
that there are two separate mechanisms giving rise to the SLSA1 and temperature-
sensitive phenotypes for splicing to A1. We have also noted enhanced accumulation of
APOBEC3 G/F mutations in the deep-sequencing data set with the SLSA1 mutant,
consistent with reduced vif mRNA resulting in reduced levels of Vif (data not shown).
Splicing in transfected cells. The comparison between the SLSA1 mutant and WT
NL4-3 was repeated using transfected 293T cells, and essentially identical splicing
patterns were observed (data not shown). This and other experiments showed that the
splicing quantification assay for HIV-1 gives similar results in comparing asynchronous
viral replication in CEMx174 cells or after transfection of 293T cells. Performing the
assay in transfected cells has the potential to allow splicing analysis of mutant viral
genomes that are incapable of infection and replication in a permissive cell line.
Comparison of splicing in T/F viruses.Most HIV-1 splicing studies have used strain
NL4-3, a subtype B chimeric virus and a laboratory strain (30). We asked if splicing in
HIV-1NL4-3 is representative of splicing in clinical isolates and if conserved splicing is
critical for infection and spread of HIV-1. To address these questions, we analyzed
splicing in a panel of subtype B transmitted/founder (T/F) viruses (31–33). We found
that overall the splicing patterns were similar among all the isolates in that the same
FIG 4 Effects of SLSA1 structural mutations on splicing. The y axis is a log scale of the fold change of splice type abundance of SLSA1 mutant
relative to WT NL4-3; the x axis shows the pattern of splice donors and acceptors and the transcript type in the 4-kb and 1.8-kb class with that
pattern. A missing bar indicates that the splice type did not occur in the SLSA1 mutant.
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splice site acceptors and donors were used, including for the small exons, but with
examples of surprising ranges of variability. In these analyses, we used values obtained
from three different experiments with strain NL4-3 to account for experimental vari-
ability.
The range of A1 usage in the T/F viruses is comparable to that in NL4-3, while
splicing from D1 to A2 varies from near 0 to about 60 percent of total transcripts (Fig.
6A). D2 and D3 are utilized in proportions comparable to those seen with NL4-3 and in
percentages that correlate closely with the use of upstream A1 or A2. Thus, the
high-frequency use of D3 results in most of the high A2 utilization turning into
downstream transcripts, with the level of residual vpr transcripts showing only modest
variability in spite of the variability in the use of A2 (Fig. 6B).
One isolate, sample 42, indicated by the red arrow in Fig. 6A, has a G-to-A transition
at the donor site D3 that disrupts the donor consensus sequence. It would be expected
FIG 5 Combined effects of temperature and SLSA1 mutation. (A) The histogram shows the ratio of the percentage of each 1.8-kb transcript that
utilizes A1 relative to the 37°C WT sample. (B) Ratio of the percentage of all 1.8-kb transcripts from SLSA1 mutant samples relative to the 37°C
SLSA1 mutant sample.
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that with the knockdown of D3 usage, transcripts spliced to A2 would accumulate,
resulting in increased vpr transcripts and very few transcripts with small exon 2.
However, this was not the case. The change to D3 corresponded with greatly decreased
splicing to A2 (Fig. 6A). There are no obvious sequence changes in this virus that would
explain reduced use of A2. This suggests either that there is a connection between the
recognition of D3 as a splice donor and the use of A2 as a splice acceptor, as predicted
by the concept of exon definition, or that some unrecognized sequence change has
independently downregulated A2 use in this isolate. Thus, in spite of a mutated D3 site
and low usage of A2 in this virus, vpr transcript levels are near a normal level (Fig. 6B).
Splicing to A3/tat spanned a range from less than 1% to greater than 11% (Fig. 6C).
There are four A4 splice acceptors, named A4a to A4d (Fig. 6D). There was greater
variety in A4 usage than in any other acceptor, and different viruses showed different
A4 splice site preferences. There was also a higher degree of sequence variability
around these acceptors. The differences in use were partly compensatory in that total
A4 usage varied only around 3-fold while the use of any one site varied up to 10-fold.
The relative usage of the two A5 acceptors (A5 much greater than A5b) was similar
between the different strains, with A5 always being the predominant splice acceptor
but varying from less than 60% to more than 80% (Fig. 6E). Thus, the relative amounts
FIG 6 Splicing in transmitted/founder viruses. (A) Ranges of A1, A2, and small exon usage in eight
transmitted/founder viruses compared to NL4-3. SX1, small exon 1; SX2, small exon 2. NL4-3
samples are from three separate experiments; the red dot indicates the sample run in the
transmitted/founder experiment. Results shown are for 1.8-kb transcripts. The red arrow indicates
sample 42, which has a mutated D3 sequence. (B) vpr transcripts in transmitted/founder. (C to E)
Usage of A3, A5, and A4 variants in transmitted/founder virus, 1.8-kb transcript class.
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of the mRNAs for the different viral proteins were generally similar, with the RNAs for
Tat and Rev showing the greatest variability. These results confirm that there is a core
set of just over 50 major spliced RNA products that define the conserved HIV-1 RNA
expression program.
Detection of cryptic/rare splicing events.While the main donor and acceptor sites
are well defined, we identified missplicing, particularly to the nearby bases around all
of the major donor and acceptor sites. In addition, there was a low-level background of
rarely used acceptor sites across the genome, interspersed with hot spots. It has been
reported previously that blocking a canonical splice acceptor or donor site leads to
activation of cryptic sites (2, 34, 35). While we did not test this phenomenon directly,
we note that the virus with the defective D3 donor site (sample 42) did not activate a
substitute donor site for D3 or an alternative acceptor for A2. Even the T/F viruses in the
extremes of low or high acceptor usage did not activate significant cryptic donor or
acceptor sites. A scan for rarely used acceptor sites in all of the T/F viruses identified
sites used at various frequencies, and the proportions of proximal alternative acceptor
sites compared to use of the canonical acceptor sites for each of the transcripts for viral
proteins are shown in Fig. 7. Rare acceptors within the normally unspliced gag-pro-pol
(GPP) sequence were also compared to total transcripts. Transcripts with rare splice
sites made up a very small proportion (less than 1%) of total transcripts both in NL4-3
and in this panel of T/F viruses.
An unusual set of rare splicing events was observed in both NL4-3 and all T/F viruses,
in which the apparent order of splicing was reversed. Splicing from D2 to A1 and from
D3 to A1 or A2 was observed, as well as from D4 to all upstream acceptors. This
out-of-order acceptor use suggests transsplicing, where a donor from one transcript
splices to an acceptor in a different transcript. In the 1.8-kb size class of the NL4-3
isolate, transsplicing to A1 made up 0.006% of total transcripts, and 0.3% of all reads
had a D4 transsplice to an upstream acceptor. Acceptor usage in these D4 transsplices
was similar to acceptor usage from D1, as shown in Fig. 2A. In these cases, the region
between A5 and D4 becomes yet another small exon. These additional small exons
skew toward the 1.8-kb transcript class, at a frequency six times greater than that of the
4-kb transcripts for transsplices from D2 or D3 to A1 and three times greater for
transsplices from D4. Remarkably, consecutive transsplicing events could also be
detected in rare transcripts, such as D4 to A2 followed by D3 to A2.
It has been observed that reverse transcriptase and/or PCR template switching can
create transsplicing artifacts between regions of sequence identity (36, 37). We do not
believe this is the cause of the transsplices we have observed between these canonical
splice sites. We looked for evidence of artifactual apparent transsplicing. There are
regions of exact identity to portions of several canonical acceptor and donor sites in
some of the T/F viruses. Isolates 43 and 47 have a duplicate post-A1 sequence 166
FIG 7 Cryptic acceptor usage as a percentage of major acceptor usage in transmitted/founder viruses
and NL4-3. Transcripts with cryptic acceptor sites are shown as a percentage of noncryptic transcripts
using the comparable major acceptor site with the same open reading frame. Cryptic acceptors in the
gag-pro-pol (GPP) sequence are compared to total transcripts.
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nucleotides upstream of the actual A1 site. In addition, isolate 42 has a duplicate pre-D2
sequence 24 nucleotides upstream. All have 10 nucleotides of exact sequence identity,
and yet they were never found in combination with a canonical splice donor or
acceptor. Thus, the transsplicing is linked to the functional donor and acceptor sites
and not regions sharing sequence identity with these sites. Additionally, we reasoned
that if template switching were random in regions of sequence similarity, we should see
a high proportion of other random events near the transspliced sites; however, when
we scanned for nearby transsplices, we found none. Taken together, this leads us to
conclude that the transsplicing that we observed is not artifactual but rather a measure
of errors in splicing by the host cell machinery.
We asked if transsplicing occurs only in cis, i.e., between transcripts in close
proximity as they are consecutively transcribed from a single provirus, or if it could
occur in trans between transcripts from proviruses at different integration sites. To
address this question, we pseudotyped HIV-1 subtype C Δenv particles with the
vesicular stomatitis virus (VSV) G envelope protein and used this virus to infect 8E5 cells.
8E5 cells have a single stably integrated HIV-1 subtype B genome. 8E5 and the subtype
C virus generated from pZM247Fv2 have sequence dissimilarities that can identify a
change from a donor of one viral RNA to an acceptor of another viral RNA. We
harvested total cellular RNA from the dually infected 8E5 cells and used it in the splicing
assay, with forward and reverse primers specific for 8E5 and pZM247Fv2. Our results
found transsplicing from both the 8E5 virus to the pZM247Fv2 virus and vice versa,
suggesting that trans-transsplicing between transcripts from different proviruses is
possible.
Splicing in subtype C. We adapted the assay to quantify splicing in this subtype C
strain and found that splicing for virus generated from the pZM247Fv2 clone is very
similar to virus generated from the pNL4-3 clone (subtype B). Donor and acceptor sites
were precisely conserved. The relative abundance of splice acceptor usage is also very
similar (Fig. 8), as is usage of the small exons. The splicing differences seen between the
4-kb and 1.8-kb sizes in NL4-3 are also seen in pZM247Fv2. A previous study found high
variation in A4 splice site usage among subtypes and samples (16, 38). In this single
sample, we did not see any new splice site usage, although the pZM247Fv2 sequence
has a point mutation that completely inactivates A4d.
Splicing quantification in SIVmac239. We next adapted the assay to quantify
splicing in SIVmac239. SIVmac239 has a more complicated splicing pattern than HIV-1
(Fig. 9). Though generally very similar to HIV-1, SIVmac239 includes an expanded 5= UTR
with an optional intron upstream of D1, here called small exon 0 (SX0). We began by
using a random reverse primer to find the splice junctions and then designed primers
that would pick up the 1.8- and 4-kb size class equivalents, as in the HIV-1 assay. Like
the HIV-1 assay, the SIVmac239 assay uses Primer ID-tagged reverse primers specific to
each size class and a forward primer 5= of D1, which is also the major splice donor.
Additionally, a second forward primer 5= of D0 was used in separate reactions with each
reverse primer to quantify splicing from D0.
Most SIVmac239 acceptors and donors align with and act analogously to HIV-1
acceptors and donors (Fig. 10). The relative acceptor usage is mostly similar to that of
HIV-1, except that in SIVmac239, A5 was used even more frequently in both size classes,
such that most spliced transcripts use A5 as the final acceptor, whether by direct
splicing from D1 or by including the small exons (Fig. 10B).
The two small exons SX1 and SX2 are conserved, though in SIVmac239 additional
donors and acceptors create a third small exon (called here SX3) due to the presence
of the extra gene vpx. Two of these small exons overlap SX1 (using A1 and either D2
or a donor at position 5514) and SX2 (using either A2 or an acceptor at 6018 and D3).
The third small exon spans positions 6411 to 6551. Thus, an SIVmac239 transcript can
have up to three of these small exons, and all possible combinations of the three small
exons are observed. In SIVmac239, A2 (and SX2) is linked to vpx, a gene not present in
HIV-1 and placed between vif and vpr. An additional splice acceptor site, A6411, is used
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to make vpr transcripts, and this splicing event activates D6551 to make SX3. In both
SIVmac239 and HIV-1, a greater fraction of splices to the vpr acceptor remain as vpr
transcripts in the 4-kb class, while in the 1.8-kb size class use of A6411 more often
activates D6551 to make SX3; however, in contrast to the high use of D3 to make SX2
in HIV-1, in SIVmac239 SX3 is seldom made even in the 1.8-kb class—most splices to
A6411 remain vpr transcripts (compare Fig. 10E and 2C). It is worth noting that splicing
to vpx is similar to the upstream vif and not the downstream vpr in the high use of the
proximal donor site (D3) in both size classes, leaving little vpx mRNA (Fig. 10C and D).
There is no splicing analog to SX0 in HIV-1. In contrast to the creation of the small
exons SX1 and SX2, which are generated after splicing to A1 or A2 followed by splicing
from D2 and D3 (respectively), inclusion of SX0 results from not splicing. Quantification
using the primer upstream of D0 shows that the 85-nucleotide-long D0-A0 intron is
FIG 9 SIVmac239 splice patterns and primer locations. Light blue, D0 forward primer; blue, D1 forward primer; red, 1.8-kb class Primer ID-tagged reverse primer;
green, 4-kb class Primer ID-tagged reverse primer. Gray boxes are small exons or sequences that may or may not be present in the respective transcripts. The
image is not drawn to scale, but relative locations are correct.
FIG 8 Quantification of splicing in subtype C strain pZM247Fv2. (A) Acceptor usage from D1 in the two
size classes. Circles represent all transcripts in the size class. (B) Circles represent the total splices from D1
to A1. Shown are proportions that splice again at D2 and those that remain vif transcripts. (C) Circles
represent the total splices to A2 and the proportions that splice again at D3 compared to those that
remain vpr transcripts. (D) Circles represent all transcripts in size class. Shown are proportions of
transcripts that contain either one, both, or no small exons. SX1, small exon 1; SX2, small exon 2.
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retained in most transcripts: 73.6% in the 1.8-kb class and 84.6% in the 4-kb class (Fig.
10A). Although D0 can splice to acceptors other than A0, it only rarely does so (0.51%
in the 1.8-kb class, 0.075% in the 4-kb class). This suggests that activation of D0, unlike
D1, is tightly coupled to the use of the proximal splice acceptor A0.
There are some quantification limitations in the SIVmac239 splicing assay due to the
limited read length of the MiSeq platform. Although quantification of splicing from D1
FIG 10 Quantification of splicing in SIVmac239. (A) Acceptor usage from D0 in the two size classes.
Yellow represents the proportion of transcripts that splice from D0 to A0; black represents the proportion
of transcripts that splice directly from D0 to an acceptor other than A0; orange represents the transcripts
that do not splice from D0 to A0. (B) Acceptor usage from D1 in the two size classes. Circles represent
all transcripts in the size class. (C) Circles represent the total splices from D1 to A1. Shown are proportions
that splice again at D2 and those that remain vif transcripts. (D) Circles represent the total splices to A2
and the proportions that splice again at D3 compared to those that remain vpx transcripts. (E) Circles
represent the total splices to A6411. Shown are proportions that splice again at D6551 compared to
those that remain vpr transcripts. (F) Circles represent all transcripts in the size class. Shown are
proportions of transcripts that contain any small exons compared to those that splice directly to the final
acceptor.
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is similar in HIV-1 and SIVmac239, with most splice variants identifiable, the increased
length of SIVmac239 between donors and acceptors makes some spliced variants too
long to fully catalog, so some long transcripts (A3 with small exons) are grouped
together. Measuring splicing from D0 has additional limitations in that the length of the
forward read just reaches D1, so all splicing from D1 must be quantified in the reverse
read, and this is not sufficient to separate splices from D1 to A1, A2, and A3. Spliced
RNAs quantified from D0 either must splice from D0 directly to some downstream
acceptor other than A0 or must also splice at D1 to be short enough to be sequenced.
It is possible that there are transcripts that splice from D0 to A0 but then remain full
length downstream, an RNA variant that would not be detected using the current
approach.
DISCUSSION
We have developed a new HIV-1 splicing assay that utilizes the MiSeq deep
sequencing platform and Primer ID technology to efficiently and accurately quantify
HIV-1 splicing. The depth of sequencing data combined with template indexing (Primer
ID) makes it possible to identify and quantify even low-abundance variants. This assay
is unique in its ability to simultaneously quantify multiple splicing events in HIV-1 RNA
transcripts in the context of viral infection with a total of just three primers. It is
noteworthy that this assay also works in transfected 293T cells, allowing quantification
of mutated viral genomes that are incapable of productive infection. The assay has
been used to measure splicing in infected primary T cells and dendritic cells, and the
results were comparable to the splicing seen in CEMx174 cells (C. Miller, R. Gummuluru,
A. Emery, and R. Swanstrom, unpublished data), validating the cell line model. This is a
moderate-throughput assay—24 samples can be multiplexed in a single deep-
sequencing reaction—that will allow it to be used to screen and compare the activities
of mutations or compounds for their effects on splicing.
It is useful to compare this new assay using the MiSeq platform to previously
described assays. Given the complexity of HIV-1 splicing, we will limit this comparison
to assays that are capable of capturing most of that complexity, specifically the original
RT-PCR/gel sizing assay of Purcell and Martin (2) and the more recent use of the PacBio
next-generation sequencing platform described by Ocwieja et al. (3). While the RT-PCR/
gel sizing assay is the simplest, it relies on size for the identification of the splicing
events, some of which can comigrate, and has limited sensitivity to detect minor
variants. Also, the number of mRNA templates queried is not known, making the
procedure prone to PCR skewing. For these reasons, next-generation sequencing
platforms offer the opportunity to capture much more information about splicing and
represent a natural evolution whereby new technology allows the reexamination of
longstanding questions to gain a greater depth of understanding.
The MiSeq assay and the PacBio assay share the features of an initial cDNA synthesis
reaction followed by amplification and sequence analysis. MiSeq sequencing is suffi-
ciently accurate to allow the use of Primer ID, which allows correction for PCR skewing
and determines the number of mRNA templates actually sequenced. PacBio is not yet
amenable to Primer ID due to its high level of error, and therefore it is necessary to do
endpoint dilution PCR of isolated templates (in droplets) to avoid PCR skewing.
However, this system cannot account for the number of mRNA templates that are
sequenced, which results in PCR resampling during sequencing. Both systems suffer
from the low processivity of RT, which results in an underestimation of splicing events
that are detected based on a longer cDNA; in our assay, cDNA products range from
about 300 to 1,100 nucleotides. We have focused our assay on the large majority of
splicing events that we detected with just three primers; the PacBio assay included the
use of more primers, which allowed the detection of an unusual 1-kb size class of
spliced RNAs (discussed below).
Within the individual 1.8- and 4-kb size classes, relative transcript abundance is
similar in the two assays, but they share two important weaknesses: the inability to
quantify the 1.8-kb transcript class relative to the 4-kb transcript class or to quantify
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spliced transcripts versus unspliced transcripts. Size class quantification is a compli-
cated problem, as there are no sequences in the 4-kb class of transcripts that are not
also present in either the 1.8-kb class and/or unspliced transcripts. Given the inherent,
but different, limitations of the MiSeq and PacBio platforms, it has been necessary to
add a complementary assay to each data set to obtain a more complete view of viral
populations. The PacBio approach has been linked to a transcriptome sequencing
(RNA-seq) data set in which oligo(dT)-primed cDNAs of whole-cell RNA are analyzed by
short reads over their entire length (3, 39). A feature of using RNA-seq is that the lack
of processivity in the cDNA synthesis step by reverse transcriptase requires a correction
of observed to calculated frequency of the longer cDNAs (up to 9 kb), making it difficult
to measure small differences with confidence. To complement the use of the MiSeq
platform, we have explored the use of a random cDNA primer linked to amplification
with the same upstream primer just 5= to D1. This allows a comparison of all transcripts,
spliced or unspliced. In this analysis, we estimate that about 22% of the spliced
transcripts are in the 1.8-kb size class and 78% in the 4-kb size class (unpublished
observation). Estimation of the ratio of unspliced to spliced viral RNA appears to be
confounded in this system by abortive or incompletely transcribed and processed reads
(40, 41), giving a higher-than-expected size of the unspliced population. It is likely that
the estimation of the ratio of different size classes and spliced to unspliced will be
sensitive to the bias of whatever method is used, in which case it will be important to
compare several methods or to focus on the use of a sensitive and reproducible
method that allows the detection of differences as experimental conditions are
changed.
In its current form, the MiSeq assay relies on just three primers; we have chosen not
to include another primer to detect either the direct splice from D1 to A7/nef or to look
for the 1-kb spliced RNA size class, although additional primers could be included to
capture these events. Regarding direct splicing from D1 to A7/nef, these are splicing
events that are part of the canonical splicing program but that occur at a low
percentage. Our data obtained with the random reverse primer suggest that D1 to A7
splices represent only about 0.4% of all spliced transcripts. Therefore, we conclude that
while not exhaustively inclusive, this new MiSeq assay captures virtually all essential
canonical splicing events and can be used to sensitively measure changes in splicing.
Similarly, we have chosen not to use an additional primer to probe for the 1-kb
spliced RNA. These smaller RNAs have been previously described (42, 43) and were seen
with the HIV-189.6 isolate but generally thought not to be conserved among isolates (3).
We did not detect similar spliced RNAs either in the NL4-3 isolate or in the SIVmac239
isolate using the random reverse primer approach. For this reason, we have chosen not
to include another primer (which would require a separate amplification) to detect
what appears to be poorly conserved splicing events outside the canonical splicing
program. However, the existence of the previously uncharacterized 1-kb RNAs does
suggest that using an approach like the random reverse primer would allow a more
systematic examination of the question of any as-yet-undetected conserved splicing
events, which must exist at a low level if at all.
Using our assay, we quantified splicing patterns in the laboratory strain NL4-3 and
observed that usage of splice acceptors A1 and A2 is temperature sensitive. We linked
a specific RNA secondary structure, SLSA1, to the efficiency of splicing at its proximal
acceptor site (A1). Finally, we used this new assay to analyze splicing in a panel of
subtype B transmitted/founder viruses, a subtype C isolate, and an SIVmac isolate and
found that splice donor and acceptor sites are well conserved, though frequency of use
varied. Following, we discuss observations and issues raised given these very precise
measures, based not on the total number of sequence reads but rather on the actual
number of mRNA templates sequenced, of relative splice site usage.
We quantified splice acceptor site usage in NL4-3 and found that of the two small
exons made by using D2 or D3, D2 usage was consistent in both transcript size classes
but D3 (D6551 in SIVmac239) was not: in the 1.8-kb size class most splices to A2 activate
splicing from the adjacent D3, but in the 4-kb size class about one-half of the D1-A2
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spliced RNAs remain as vpr transcripts without activating D3 (Fig. 2). In contrast, splicing
to A1/vif activates D2 most of the time in both RNA size classes. This suggests a link
between D3 usage and downstream D4 usage, which has not yet been explored. This
difference is even greater in SIVmac239, where splicing to A2/vpx activates D3 in both
size classes, similar to what happens with splicing to A1/vif, but splicing to the new
downstream A6411/vpr acceptor activates the adjacent D6551 donor in only a minority
of cases and hardly at all in the 4-kb size class. Thus, there is a strong gradient effect
of linked donor activation across the center of the viral RNA. Nonsense-mediated decay
(44) could play a role in degrading 1.8-kb vpr transcripts, thus leaving mostly 4-kb vpr
transcripts, but this raises the question of why the same rules do not apply to 1.8-kb
and 4-kb vif and vpx transcripts. Alternatively, the mechanism that suppresses splicing
from D4 (allowing the formation of the 4-kb size class) may also influence the use of the
proximal upstream donor site in both HIV-1 and SIV. There are several other examples
in which splicing is differentially suppressed in the 4-kb size class that support this
notion (see below).
The purpose of the conserved small exons remains to be clearly elucidated. They are
conserved across subtypes and in SIVmac239, including for the additional vpx gene (Fig.
1 and 9) (45, 46), as well as in the T/F viruses analyzed (Fig. 6), consistent with strong
selective pressure for their presence. Previously cited studies to define their functional
importance are, as mentioned earlier, inconclusive (1, 6–9). It is not clear whether
donors D2 and D3 exist to downregulate the amount of vif and vpr mRNAs or if D2 and
D3 are required for exon definition (47) to activate A1 and A2, respectively. The
transmitted/founder virus isolate 42 with the mutant D3 argues for exon definition, i.e.,
knockdown of D3 reduced A2 usage, a result that has also been seen in model systems
(10, 14, 48); however, in another study with a different HIV-1 isolate, we saw that a
reduction in D3 usage led to accumulation of vpr transcripts (data not shown). Viruses
that differ dramatically in their use of vpr/A2 still produce similar levels of vpr mRNA
(Fig. 5A), consistent with the idea that splicing regulation can be accomplished by
different mechanisms even for the same site. More work is needed to clarify the roles
of D2 and D3 and the purpose of the small exons given their conservation across clades
and in at least some nonhuman primate lentiviruses.
There are 62 spliced mRNA species that are well conserved among the different
isolates. Given the conservation of these alternative splicing pathways for HIV-1, we
were interested in using temperature shifts to probe features of their control and found
that the use of A1 and A2 are each, but differentially, sensitive to temperature changes.
The differential responses to temperature in the use of A1 and A2 are consistent with
suboptimal interactions of these splice acceptor sites with the host cell splicing
machinery, but in different ways. It is worth noting that these two splice sites are
indirectly downregulated with the high-frequency use of D2 and D3, suggesting that
A1 and A2 have been selected to be suboptimal for interactions near the point of
instability. A secondary structure proximal to A1 was seen to be critical to splicing
based on the observation that two mutations designed to decrease its structural
stability reduced splicing in a way that was additive with the effect of temperature (Fig.
5). These data do not rule out the possibility that the mutations affect other features of
splicing, such as binding by an unknown factor, and further work is required to fully
understand the role of this hairpin in regulating A1 usage. It would also be interesting
to use deep-sequencing technologies to see if temperature shifts reveal similar changes
among alternative splicing pathways of cellular RNAs.
Our data suggest that the SLSA1 structure is important to A1 usage; other splice
acceptors and splice control elements are also located in or near structural features, and
many of these regions have been studied for their ability to bind cellular splice factors
(49, 50). It will be informative to continue to characterize the roles that these and other
structures play in splicing regulation by creating mutations that alter either structure or
cellular factor binding sites. One such study has involved the knockdown of the cellular
factor heterogeneous nuclear RNP (hnRNP) H1 with the observation that splicing to
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A1/vif is most affected by limiting this factor (S. Kutluay, P. Bieniasz, A. Emery, R.
Swanstrom, unpublished data).
As most previous HIV-1 splicing studies have used HIV-1 strain NL4-3 as a model, it
is significant that we observed NL4-3 splicing to be comparable to the mean splicing
patterns seen in the T/F virus panel and in a subtype C isolate (Fig. 6 and 8). This finding
validates the use of NL4-3 in other studies of splicing regulation. In addition, some
general conclusions can be drawn from the T/F virus splicing data. Overall, splicing
patterns are the same. Acceptors and donors remain constant, but there is surprisingly
high variability in their usage. In addition, there are examples of splicing events within
a strain that are not conserved between strains, with some examples being the
reported 1-kb size class in strain 89.6 (3), the SX0 exon in strain SIVmac239, and greater
than 50% tat transcripts in strain NDK (data not shown). The idea that splicing is a
tightly regulated and carefully balanced process (1) needs reexamination. The variance
in transcripts in these different strains of virus suggests that if a virus meets a threshold
level for each transcript type, it can be transmitted and continue to replicate.
Previous studies suggested that cryptic splicing will be activated if/when usage of a
regular acceptor is changed or blocked (1, 2, 34, 35). Our data do not support this
concept. Cryptic splicing remained negligible across the entire panel of T/F viruses, in
spite of functionally important changes in acceptor and donor consensus sequences. In
no case was a cryptic donor or acceptor substitute activated above background levels.
HIV-1 acceptors have been classified as weak (51, 52), and clearly they diverge from the
cellular splicing consensus sequence and branch point rules (1, 53, 54); however, they
are still consistently recognized as major splice sites above the background noise. This
suggests that many as-yet-unexplained factors contribute to HIV-1 splicing regulation.
We found evidence of transsplicing in NL4-3 and all the transmitted/founder viruses.
Our assay can detect transsplicing up to a maximum length of four small exons, so the
full extent of transsplicing may be greater than what we have seen. The overall
frequency of transsplicing was surprisingly high. At a frequency of 0.3% in the 1.8-kb
class, total transsplicing occurred more often than several of the canonical spliced
transcript types. Transsplicing in HIV-1 has been previously reported (55, 56), though
not between HIV-1 RNAs, which we infer must have occurred given the altered order
of the exon segments and between transcripts of different proviruses. Whether the
cryptic splicing that we observed here has biological significance or is merely a
stochastic occurrence between two viral transcripts in close proximity is unknown. By
observing transsplicing between transcripts from two different proviruses, we were
able to show that this phenomenon occurs beyond a flurry of cotranscriptional splicing
between adjacent transcripts. Also, the greater level of transsplicing in the 1.8-kb class
than in the 4-kb class provides yet another example in which splicing is partially
suppressed in the context of retaining the D4/A7 intron. The effects on suppressing the
use of these viral splice donor sequences are reminiscent of the observation that there
is a general suppression of splicing (i.e., intron retention) in cellular transcripts during
HIV-1 infection (39). One model to explain these phenomena is that binding of the RNA
by Rev to move the RNA to the Crm1 export pathway may suppress proximal splice
donor activation and that Rev may fortuitously bind to some cellular pre-RNAs.
In conclusion, developments in deep-sequencing technology now make it possible
to quantify the complexity of HIV-1 splicing in depth and to study the effectors of
splicing with greater precision than previously possible. Here we report some examples
of its utility and suggest potential uses in further studies.
MATERIALS AND METHODS
Viruses. A panel of full-length transmitted/founder (T/F) HIV-1 infectious molecular clones was
obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from John Kappes (31–33,
57). Clones are identified by the last two digits of their identification number. The infectious clone pNL4-3
was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from Malcolm Martin
(30), and the SLSA1 mutant virus was made as described by Pollom et al. (22). Virus was produced by
transfecting 293T cells using 4 g of a viral DNA clone/well of a 6-well plate for the SLSA1 experiment
and 1 g/well for the T/F viruses, using FuGene (Promega) transfection reagent as per the FuGene
protocol database. At 48 h after transfection, the medium was removed and filtered through a 45-m
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filter and then frozen in aliquots at 80°C for later use. pZM247Fv2 was obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH, from Beatrice Hahn (57). A partial env deletion of this
clone, pZM247v2Δenv, was obtained from Sarah Joseph. VSV G-pseudotyped pZM247v2Δenv virus was
produced by cotransfecting 293T cells with 5 g each of the pZM247v2Δenv plasmid and a VSV G
expression plasmid in a T75 flask, as per the FuGene protocol database, and harvested and filtered as
described above. A molecular clone of SIVmac239 was obtained from Ronald Desrosiers (58) and used to
produce virus by transfection.
Cells. CEMx174 cells were used for HIV-1 infections. Cells were cultured in RPMI plus 10% fetal bovine
serum (FBS) with added penicillin and streptomycin. For the SLSA1 mutant/temperature gradient
experiment, 2  106 cells were pelleted and resuspended in 800 l of medium with either the SLSA1 or
NL4-3 virus, incubated for 45 min, and then brought to a total volume of 50 ml of RPMI with FBS. The
cells were then incubated at 37°C for 4 days, until syncytia were evident. An aliquot of 10 ml of each
culture (with cells) was put into each of 3 flasks and incubated for 6 h at 33°C, 37°C, or 41°C, and then
the cells were harvested for RNA extraction. The T/F virus molecular clones were transfected into 293T
cells plated the day before at 5  105 cells/well of a six-well plate. Cells were harvested 48 h
posttransfection for RNA extraction. 8E5 cells (8E5 cells were obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH, 8E5/LAV, from Thomas Folks [59]), a clonal cell line producing virus
from a single defective provirus, were superinfected with VSV G-pseudotyped subtype C pZM247v2Δenv
virus. A total of 5  107 8E5 cells were pelleted and resuspended in 40 ml of medium with the
pseudotyped virus, and aliquots were harvested between 1 and 3 days postsuperinfection.
RNA extraction, cDNA synthesis, and Illumina MiSeq library preparation. Total cellular RNA was
extracted using the RNeasy Plus minikit (Qiagen), with the QIAshredder to homogenize cell lysates
(Qiagen) and including 1% -mercaptoethanol in the lysis buffer. Primers used for cDNA synthesis for
NL4-3 and 8E5 cells, the T/F strains, pZM247v2Δenv, and SIVmac239 are shown in Tables 1 and 2. All
primers were resuspended at a concentration of 10 mM. Indexed primers were obtained from Integrated
TABLE 1 Primers used in this study
Primer use and name Sequence
SLSA1, temp, T/F NL4-3, 8E5 primers
idx_fp GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAGNNNNTGCTGAAGCGCGCACGGCAAG
l_idx_4r GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)GTACTATAGGTTGCATTACATGTACTACTTAC
l_idx_1.8r GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)CAGTTCGGGATTGGGAGGTGGGTTGC
T/F 4-kb reverse primers
l_idx_39r GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TAAAGGTTGCATTACATATATTACTTAC
l_idx_42r GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TAAAGATTGCATTACAGATGCTACTTAC
l_idx_43r GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TAAAGAGTTCATTACATGCACTACTCAC
l_idx_46r GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TAAAGTTTGCATTACAAGCACTACTTAC
l_idx_48r GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TAAAGCTTGCATTACATATACTACTTAC
T/F 1.8-kb reverse primers
idx_18_43 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TCCCCTCTGGGCTGGGGGGCGGATTGC
idx_18_44 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TCGGGGCTGGGAAGCGGGTTGC
idx_18_45 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TCGGGGCTGGGAGGCGGGTTGC
T/F forward primers
lidx_fp_I GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAG(N14)TGCTGAAGCGCGCACGGCAAG
TF_42_fp GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAG(N14)TGCTGAAGCGCGCACAGCAAG
TF_47_fp GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAG(N14)TGCTGAAGCGCGCGCGGCAAG
Subtype C pZM247Fv2
idx_C3_4rp GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TTCAAGCATTACATCTACTATTTGGTACTTAC
idx_C3_18rp GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)TCGGGTCCCCTCGAGTTTGGGATAAGGGTTGC
idx_C3_fp GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAGNNNNTGCTGAAGTGCACGCAGCAAG
SIVmac239
SIV_f_DO GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAGNNNNGCCCTGGGAGGTTCTCTCCA
SIV_f_D1 GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAGNNNNAGGAAGAGGCCTCCGGTTGCA
SIV_rp_18 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)CGGGTCCTGTTGGATATGGGTTTG
SIV_rp_4k GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)ATTCCCAAGACATCCCATACTTAC
Random reverse
uni_rp GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT(N14)
Illumina library
UniAdpt AATGATACGGCGACCACCGAGATCTACACGCCTCCCTCGCGCCATCAGAGATGTG
IllIndAdpt CAAGCAGAAGACGGCATACGAGATNNNNNNGTGACTGGAGTTCAGACGTGTGCTC
ADPT_2a GTGACTGGAGTTCAGACGTGTGCTC
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DNA Technologies Custom Oligos, with hand mixing to optimize random base incorporation. For the
SLSA1 and temperature experiments, 2 g of total cellular RNA from each sample was mixed with 1 l
of 10 mM deoxynucleoside triphosphates (dNTPs), 0.5 l of the indicated reverse primer, and distilled
water (dH2O) to 13 l. The samples were heated to 65°C for 5 min and then held at 4°C. To each tube
was added 1 l of 0.1 M dithiothreitol, 1 l RNaseOUT (ThermoFisher), 4 l of 5 SuperScript III RT buffer,
and 1 l SuperScript III Reverse Transcriptase (ThermoFisher), and then the tubes were heated to 55°C
for 1 h followed by 70°C for 15 min. An aliquot of 1 l RNase H (ThermoFisher) was added to each sample,
which was then incubated at 37°C for 20 min. cDNA synthesis for the T/F virus samples and SIVmac239
was the same, except that 4 g of total cellular RNA was used. cDNA synthesis for the pZM247v2Δenv-
infected 8E5 cells was done using two reverse primers for each size class, one specific to the 8E5 virus
(the NL4-3 primers) and one specific to the pZM247Fv2 virus. cDNAs were purified, and the Primer ID
cDNA primer was removed using Agencourt RNAClean XP beads (Beckman Coulter) as per the protocol
with a 2:1 ratio of beads to sample volume. Illumina libraries for the SLSA1 mutant and temperature
gradient samples, VSV G-pseudotyped pZM247v2Δenv, and SIVmac239 were made using two successive
rounds of PCR amplification. For the first PCR, 1 g cDNA template, 1 l dNTPs, 2.5 l ADPT_2a reverse
primer, 2.5 l idx_fp forward primer, 0.4 l KAPA Robust Hot Start Polymerase (KAPA Biosystems), 7.5%
dimethyl sulfoxide (DMSO), 10 l KAPA A buffer, 10 l KAPA Enhancer 1, and dH2O to 50 l were
combined and cycled with an initial denaturation at 95°C for 5 min, followed by 3 cycles each consisting
of 95°C for 30 s, progressively decreasing annealing temperatures of 64°C, 61°C, 58°C, 55°C, and 52°C for
15 s, and 72°C for 2 min, and then 5 more cycles with an annealing temperature at 50°C. The final
extension was at 72°C for 10 min. PCR products were purified and primers removed using AMPure XP
Beads (Beckman Coulter) as per the protocol, using a 1.6:1 ratio of beads/PCR volume. An aliquot of 3 l
of the cleaned product from this first PCR was used as the template for the second PCR, added to 10 l
KAPA A buffer, 1 l dNTPs, 2.5 l UniAdpt forward primer, 2.5 l IllIndAdpt forward primer, 0.4 l KAPA
Robust Hot Start Polymerase, 5% DMSO, 10 l KAPA Enhancer 1, and dH2O to 50 l. Cycling conditions
were as for the first PCR but with annealing temperatures of 66°C, 63°C, and 60°C each for 3 cycles,
followed by 25 cycles with an annealing temperature of 58°C. “N”s in the IllIndAdpt forward primer are
specific sequences that bar code each sample to allow multiplexing in the Illumina sequencing reaction.
PCR products were visualized on a 2% agarose gel and then cleaned as before using AMPure XP Beads.
For T/F virus samples, 4 g of total cellular RNA was used as input to the cDNA reaction mixtures as
described above. cDNAs were forward tagged as follows. Samples containing an aliquot of 1 g of
purified cDNA, 0.5 l forward primer lidx_fp_I (or the appropriate sample-specific forward primer), 1 l
dNTPs, and dH2O to 14.8 l were heated to 75°C and then cooled in 1°C increments for 30 s until
reaching 45°C. To each sample were added 0.2 l Phusion HF, 4 l Phusion 5 buffer, and 1 l DMSO.
Samples were then heated to 45°C, and the temperature was increased in 1-degree increments every 10
s until reaching 72°C, where it was held for 10 min. Following forward tagging, the samples were purified
using DNA XP beads as described above but eluted in 23 l. An aliquot of 21.1 l of the purified tagged
forward strand was input into a second PCR mixture as above, with the following cycle changes: initial
denaturation at 95°C for 5 min; then, 3 times each touchdown cycle using progressively cooler annealing
temperatures, 95°C for 30 s, annealing at 64°C, 61°C, 58°C, 55°C, and 52°C for 15 s, extension for 2 min
at 72°C; then, 20 cycles with annealing temperature at 50°C; and a final extension at 72°C for 10 min.
Sequencing. Libraries were mixed/multiplexed and sequenced using the 300-base paired-end read
Illumina Miseq platform. Reads were sorted using the Illumina bcl2fastq pipeline (v.1.8.4) to separate the
multiplexed samples. All samples were loaded at a concentration of 8 pM with 15% PhiX double-stranded
DNA fragments to optimize cluster formation. Because of quality control features that are intrinsic to
each sequencing run, comparisons of relative abundance of spliced RNAs between samples are most
reliably accomplished when the samples are multiplexed in the same sequencing run.
Splicing analysis. Data analysis and splicing quantification were done using an in-house pipeline
written in Ruby. Using the combined data from the forward and reverse reads, this program identifies the
specific splice variant for each paired-end read and bins the reads by Primer ID to prevent skewing from
PCR resampling. The same sorting program was used for both SLSA1 mutant and temperature gradient
experiments. Separate programs were adapted to the specific primers and sequence of each T/F virus,
as well as for pZM247Fv2 and SIVmac239. Rare alternative donor and acceptor splice sites were identified
using a program that compares data reads to a reference sequence and identifies the base where a splice
TABLE 2 Primers used for each sample
Sample type or ID no. Forward primer Reverse 1.8-kb primer Reverse 4-kb primer
SLSA1 and temp expt idx_fp idx_1.8rp idx_4rp
T/F NL4-3 lidx_fp_I l_idx_1.8r l_idx_4r
40 lidx_fp_I l_idx_1.8r l_idx_39r
42 TF_42_fp l_idx_1.8r l_idx_42r
43 lidx_fp_I idx_18_43 l_idx_43r
44 lidx_fp_I idx_18_44 l_idx_4r
45 lidx_fp_I idx_18_45 l_idx_4r
46 lidx_fp_I l_idx_1.8r l_idx_46r
47 TF_47_fp l_idx_1.8r l_idx_4r
48 lidx_fp_I idx_18_45 l_idx_48r
56 lidx_fp_I idx_18_45 l_idx_39r
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discontinuity occurs and the base it splices to. Specific rare acceptor site usage was quantified using a
modification to the basic splicing identification program. These programs are available on request.
Accession number(s). Sequencing data files are available in the SRA database BioProject under
accession number ID PRJNA324601.
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